ClinicalTrials.gg
RecruitingNCT07739277Updated Aug 7, 2026

Transverse vs. Longitudinal Serratus Anterior Plane Block in Breast Surgery

An interventional study of Transverse SAP Block and Longitudinal SAP Block in Fascial Plane Block, Pain, Postoperative and Breast Surgery, sponsored by Ankara Etlik City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Pain, Postoperative by Ankara Etlik City Hospital — 7 open to participants now, 8 under way, none of them phase 3. Pain, Postoperative · Ankara Etlik City Hospital.

Planned enrollment
4th of 11
70 · median 64
Started
2026
with 8 others
No phase
11 of 15
6 open now
Registered
10th of 15
by date

Among the 15 studies in Pain, Postoperative by Ankara Etlik City Hospital, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is one of 9 that started in 2026, is one of 11 with no phase, and was the 10th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 15 studies in Pain, Postoperative by Ankara Etlik City Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pain, Postoperative by Ankara Etlik City Hospital, or all of them as a file.
02

Study summary

The aim of this prospective, randomized controlled trial is to compare the analgesic efficacy of transverse versus longitudinal ultrasound probe orientations during Serratus Anterior Plane (SAP) block in patients undergoing breast surgery. The study hypothesizes that the longitudinal approach (probe parallel to the ribs) may provide better craniocaudal spread of the local anesthetic, thereby resulting in lower postoperative Visual Analog Scale (VAS) scores and reduced opioid consumption compared to the standard transverse approach.

03

Conditions studied

  • Fascial Plane Block
  • Pain, Postoperative
  • Breast Surgery
  • Acute Pain
  • Mastectomy

Keywords

  • Serratus Anterior Plane Block
  • Regional Anesthesia
  • Postoperative Analgesia
  • Breast Surgery
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 65 years
  • (ASA) physical status I, II, or III
  • between 18 - 30 kg/m2
  • Patients scheduled for elective breast surgery
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Known allergy to local anesthetics
  • Infection at the injection site
  • Severe coagulopathy or use of anticoagulants
  • Chronic opioid use or history of neuropathic pain
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Transverse SAP Block

    Patients will receive an ultrasound-guided Serratus Anterior Plane (SAP) block at the 4th rib level. The ultrasound probe will be placed in a transverse orientation (perpendicular to the ribs). A total of 20 mL of 0.375% bupivacaine will be injected into the fascial plane.

    Procedure: Transverse SAP Block

  • Active comparator
    Longitudinal SAP Block

    Patients will receive an ultrasound-guided Serratus Anterior Plane (SAP) block at the 4th rib level. The ultrasound probe will be placed in a longitudinal orientation (parallel to the ribs in the craniocaudal axis). A total of 20 mL of 0.375% bupivacaine will be injected into the fascial plane.

    Procedure: Longitudinal SAP Block

Interventions

  • ProcedureTransverse SAP Block

    Transverse serratus anterior plane block will be performed on the patients using 20 mL of 0.375% bupivacaine under ultrasound guidance.

  • ProcedureLongitudinal SAP Block

    Longitudinal serratus anterior plane block will be performed on the patients using 20 mL of 0.375% bupivacaine under ultrasound guidance.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity

    Pain will be assessed using a visual analog scale from 0 mm (no pain) to 100 mm (worst pain) at rest. Pain assessment will be made at 4 hour after surgery.

    Time frame: 4 hour after surgery

Secondary outcomes

  1. Postoperative Pain Intensity

    Pain will be assessed using a visual analog scale from 0 mm (no pain) to 100 mm (worst pain) at rest and when coughing. Pain assessment will be made at 1, 8, 12, and 24 hours after surgery.

    Time frame: Up to 24 hours

  2. Postoperative Pain Intensity

    Pain will be assessed using a visual analog scale from 0 mm (no pain) to 100 mm (worst pain) while coughing. Pain assessment will be made at 1, 4, 8, 12, and 24 hours after surgery.

    Time frame: Up to 24 hours

  3. Total Postoperative Opioid Consumption

    The total amount of opioid consumed by the patient will be recorded.

    Time frame: Up to 24 hours

  4. Area Under Curve for Pain

    Cumulative 24-hour pain burden calculated by the trapezoidal rule

    Time frame: Up to 24 hours

  5. Assessment of Sensory Blockade Extent

    Sensory extent will be assessed using pinprick testing with a 20-gauge hypodermic needle.

    Time frame: Evaluated at 20 minutes following block administration.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
Aug 6, 2026
Primary completionEst.
Feb 8, 2027
CompletionEst.
Feb 19, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07739277
Responsible party
İbrahim Topcu (Principal Investigator, Ankara Etlik City Hospital) — Principal investigator
First posted
Jul 31, 2026
Start date
Aug 6, 2026
Primary completion
Feb 8, 2027 (estimated)
Completion
Feb 19, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

İbrahim MD Topcu
Contact
ibrahimtpc78@gmail.com
05437860316
Musa Ass. Prof Zengin
Contact
musazengin@gmail.com
05071302750

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion